APHARMAS -

Description:

This service is based on advantage of lentiviral vectors that can stably deliver genes into primary cells or cell lines with up to 100% efficiency and our Lenti-Ready^sm Technology which provides higher efficiency and more flexibility. Ready-to-use deliverables are suitable for in vitro and in vivo applications.

Advantages:

• One-stop service: from cloning to packaging
• Quick turnaround time: 4 to 6 weeks
• Cost-effective
• Custom tag and protocol acceptable
• Commercial protein production and optimization offered

Requirements:

DNA of your target gene and sequence map are needed.

Deliverables

• Virus supernatants
• Infection reference protocol

Options:

• Choice of selection marker: Puromycin or GFP or your marker
• Constitutive or inducible
• Concentration for in vivo applications
• Packaging-only service: to use your own construct with our packaging system
• Re-order of additional volume at reduced cost

Service documents (registered user only):

• General service information (Login)

Reference:

1. Overmeyer et al. Active Ras Triggers Death in Glioblastoma Cells through Hyperstimulation of Macropinocytosis. Mol Cancer Res. 2008 Jun; 6(6): 965-77
2. Russell et al. The α-Receptor for Platelet-Derived Growth Factor Confers Bone-Metastatic Potential to Prostate Cancer Cells by Ligand- and Dimerization-Independent Mechanisms. Cancer Res. May 15, 2010, 70; 4195

For more technical details and quotation, please This e-mail address is being protected from spambots. You need JavaScript enabled to view it